Jayanta Chaudhuri, MD
Internal Medicine · Niagara Falls, NYNPI 1497716492
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,132 of the $3,771 with a category attached, or 83.1%. It is spread thinly across 26 manufacturers, the largest accounting for just 18.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2020 at $1,398 and has fallen 83.5% since, to $231 in 2025.
Across 186 payments — averaging $20.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$696
- Lilly USA, LLC$672
- Esperion Therapeutics, Inc.$654
- Sanofi-aventis U.S. LLC$324
- Novo Nordisk$184
- BETA Bionics, Inc.$135
- plus $1K from 20 others
What the payments were for
- Food & beverage$3,13283%
- Education$63917%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 36 | $696 |
| Lilly USA, LLC | 44 | $672 |
| Esperion Therapeutics, Inc. | 15 | $654 |
| Sanofi-aventis U.S. LLC | 11 | $324 |
| Novo Nordisk | 11 | $184 |
| BETA Bionics, Inc. | 7 | $135 |
| AstraZeneca | 7 | $108 |
| Medtronic(2 entities) | 4 | $89 |
| Amgen | 5 | $80 |
| Amarin Pharma, Inc. | 4 | $79 |
| Abbott | 5 | $79 |
| Pfizer | 5 | $79 |
| GSK | 4 | $75 |
| E.r. Squibb & Sons, L.L.C. | 4 | $75 |
| Dexcom, Inc. | 4 | $74 |
| Novartis | 4 | $72 |
| Insulet Corporation | 3 | $54 |
| Ascendis Pharma Endocrinology Inc | 2 | $44 |
| Amneal Pharmaceuticals LLC | 2 | $37 |
| Bayer | 2 | $33 |
| Johnson & Johnson | 2 | $27 |
| Mannkind Corporation | 1 | $22 |
| Recordati_rare_diseases_inc. | 1 | $20 |
| EUSA Pharma (US) LLC | 1 | $20 |
| Xeris Pharmaceuticals, Inc. | 1 | $19 |
| Corcept Therapeutics | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SOLIQUA 100/33$107
How this compares
$3,771 in reported general payments places this provider in the 85th percentile of 9,771 internal medicine providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 60 | $83,800 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 58 | $54,439 |
| TradjentaLinagliptin | 21 | $27,351 |
| JardianceEmpagliflozin | 14 | $17,391 |
| Breo ElliptaFluticasone/Vilanterol | 12 | $9,100 |
| Metoprolol Succinate | 287 | $7,709 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 22 | $7,591 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 40 | $7,233 |
| SymbicortBudesonide/Formoterol Fumarate | 16 | $5,247 |
| Atorvastatin Calcium | 348 | $4,969 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 11 | $4,939 |
| BelsomraSuvorexant | 11 | $4,926 |
| Telmisartan | 113 | $3,833 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 131 | $3,612 |
| Levothyroxine Sodium | 217 | $3,405 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $79 | $83,80060 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $75 | $68,47981 claims |
| Boehringer IngelheimTradjenta, Jardiance | $696 | $44,74235 claims |
| AstraZenecaSymbicort | $108 | $5,24716 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $37 | $3,405217 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 9,771 internal medicine providers in New York.
Other internal medicine in Niagara Falls
- David DoveEast Hampton$12.3M
- Bruce BergerBrooklyn$3.4M
- Nicholas RobinsonBuffalo$2.9M
- Stephen SaletanNew York$2.6M
- Ziad AliNew York$2M
- Scott BeegleAlbany$1.9M
- Anthony MartinezBuffalo$1.6M
- Javier MoralesGreenvale$1.3M
- Ricky HsuNew York$1M
- James UnderbergNew York$953K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.